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OBJECTIVES The present study evaluates the long-term course of aortic valve disease and the need for
aortic valve surgery in patients with rheumatic mitral valve disease who underwent mitral
valve surgery.
BACKGROUND Little is known about the natural history of aortic valve disease in patients undergoing mitral
valve surgery for rheumatic mitral valve disease. In addition there is no firm policy regarding
the appropriate treatment of mild aortic valve disease while replacing the mitral valve.
METHODS One-hundred thirty-one patients (44 male, 87 female; mean age 61 6 13 yr, range 35 to 89)
were followed after mitral valve surgery for a mean period of 13 6 7 years. All patients had
rheumatic heart disease. Aortic valve function was assessed preoperatively by cardiac
catheterization and during follow-up by transthoracic echocardiography.
RESULTS At the time of mitral valve surgery, 59 patients (45%) had mild aortic valve disease: 7 (5%)
aortic stenosis (AS), 58 (44%) aortic regurgitation (AR). At the end of follow-up, 96 patients
(73%) had aortic valve disease: 33 AS (mild or moderate except in two cases) and 90 AR (mild
or moderate except in one case). Among patients without aortic valve disease at the time of
the mitral valve surgery, only three patients developed significant aortic valve disease after 25
years of follow-up procedures. Disease progression was noted in three of the seven patients
with AS (2 to severe) and in six of the fifty eight with AR (1 to severe). Fifty two (90%) with
mild AR remained stable after a mean follow-up period of 16 years. In only three patients
(2%) the aortic valve disease progressed significantly after 9, 17 and 22 years. In only six
patients of the entire cohort (5%), aortic valve replacement was needed after a mean period
of 21 years (range 15 to 33). In four of them the primary indication for the second surgery
was dysfunction of the prosthetic mitral valve.
CONCLUSIONS Our findings indicate that, among patients with rheumatic heart disease, a considerable
number of patients have mild aortic valve disease at the time of mitral valve surgery. Yet most
do not progress to severe disease, and aortic valve replacement is rarely needed after a long
follow-up period. Thus, prophylactic valve replacement is not indicated in these cases. (J Am
Coll Cardiol 1999;33:2003–8) © 1999 by the American College of Cardiology
A considerable proportion of patients who require mitral
valve replacement present with a coexisting pathology of the
aortic valve (AV). Rheumatic fever remains the leading
cause for combined disease (1). Early series found that
one-third of rheumatic hearts exhibited involvement of both
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mitral and AV. The rate increased to 99% when the
follow-up period was extended to 20 years (2–4). The
treatment of choice in cases in which one of the valves is less
than moderately affected is questionable. Because combined
aortic and mitral valve replacement is usually associated with
higher risk and poorer long-term survival than replacement
of either of the two valves alone (5), a higher threshold for
double valve replacement is required. In the absence of a
strict paradigm, the decision to replace more than one valve
is often made by the surgeon during operation.
To help the clinician establish a uniform policy for the
management of multivalvular involvement, we reviewed our
experience with patients with rheumatic heart disease who
underwent mitral valve replacement or commissurotomy
and were followed for an average of 13 6 7 years. The aim
of the present study was to evaluate the course of AV disease
after mitral valve surgery, including the need for further AV
surgery.
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METHODS
Study patients. Between 1975 and 1992, a total of 574
patients underwent mitral valve surgery in our cardiotho-
racic surgery division. One-hundred and sixty were excluded
from the study because of nonrheumatic valvular disease,
presence of severe aortic valve disease at the time of
operation, performance of a double aortic and mitral valve
replacement in the same session, congenital heart disease
other than congenital bicuspid aortic valve or bacterial
endocarditis (due to aortic valve deformation). Rheumatic
valve disease was present in 414 patients. Two-hundred
patients were excluded because of inadequate follow-up
procedures. Eighty-three patients died during the first
postoperative year (64 died on the day of the operation and
19 died during the following year). The remaining 131
patients with rheumatic heart disease who were followed
periodically by Doppler-echocardiography in our valvular
clinic formed the study group. Each patient was evaluated
by a preoperative cardiac catheterization and by postopera-
tive transthoracic Doppler-echocardiography examinations
(for at least one year after the surgery). Clinical data
obtained from the hospital records included age, gender,
heart rhythm, New York Heart Association functional class
and presence of concomitant medical problems (coronary
heart disease, diabetes, hypertension, hyperlipidemia and
chronic renal failure).
Cardiac catheterization measurements. All 131 patients
had undergone cardiac catheterization by standard femoral
percutaneous or brachial cut-down techniques. Before the
injection of contrast material, left ventricular end-diastolic
pressure and transvalvular gradient were obtained by the left
ventricular aortic root pull-back method.
Aortic stenosis (AS) was considered mild when the peak
gradient was 25 mm Hg or less, moderate when the peak
gradient was between 25 to 50 mm Hg and severe for a peak
gradient above 50 mm Hg. This scale was used only with
normal left ventricular function (left ventricular ejection
fraction [LVEF] equal or above 50%). In patients with
decreased LVEF, cardiac output was measured with the
Fick method, and the aortic valve area was calculated by the
Hakki formula (6). Aortic regurgitation (AR) grade was
estimated by injecting contrast material into the aortic root.
Regurgitation was qualitatively assessed on a scale 11 to 14
(7) using the right anterior oblique view. Coronary artery
disease was defined as $70% obstruction of the luminal
diameter of at least one epicardial artery by visual assess-
ment.
Echocardiographic analysis. Echocardiographic studies
were performed in a standard manner and included the
parasternal long- and short-axis views and the two-, four-
and five-chamber and apical long-axis views. Mean and
peak transthoracic gradients were calculated with the
modified Bernoulli equation (8) using continuous-wave
Doppler recordings. The aortic valve area was computed
with the continuity equation (9) using standard methods
when systolic function of the left ventricle was decreased.
In the presence of normal left ventricle systolic function
(estimated qualitatively and by measurement of fractional
shortening above 30%) the mean gradient was used to
define the severity of AS (mild #25 mm Hg, moderate
25–50 mm Hg, severe $50 mm Hg). In cases of systolic
left ventricular dysfunction, an AV area of $1.5 cm2 or
more was considered mild AS; 1.1 to 1.5 cm2, moderate
and 1.0 cm2 or less, severe (10). Aortic regurgitation
grade was estimated by integrating the continuous wave
Doppler signal (11) and the color flow mapping, as
previously described (12,13). Imaging was performed
using commercially available ultrasound systems
(SONOS 500, 1000 and 2000, Hewlett Packard, An-
dover, Massachusetts) and interpreted by a cardiologist
skilled in echocardiography.
Statistical analysis. Descriptive baseline characteristics
were summarized by frequencies and percentages or by
mean values and standard deviation. Univariate and
multivariate analyses were used to identify predictors of
deterioration of AV disease. Life table analysis based on
Kaplan-Meier was done, using the BMDP statistical
software (University of California Press) (14).
RESULTS
Average follow-up period for the 131 patients was 13 6 7
years (range 1 to 33 yr, median 13) (Table 1).
All the patients had rheumatic heart disease. Sixty-three
patients had mitral stenosis, 60 had combined mitral steno-
sis and regurgitation and 8 had mitral regurgitation. Mitral
valve replacement was performed in 101, commissurotomy
in 30 (Table 1). Forty-five patients of the cohort had mitral
commissurotomy performed a decade before the beginning
of the follow-up procedures. These patients had either
normal AV or mild disease at the time of the first mitral
valve surgery (based on preoperative cardiac angiography).
None of them had progressed according to the angiography
before the second mitral valve surgery. Thus, the follow-up
period was extended accordingly.
At the time of mitral valve surgery, 59 patients (45%) had
AV disease, 7 had AS and 58 had AR. Six patients had
combined disease. Seventy-two patients (55%) had no
evidence of AV disease (Table 2).
Abbreviations and Acronyms
AR 5 aortic regurgitation
AS 5 aortic stenosis
AV 5 aortic valve
CABG 5 coronary artery bypass grafting
Fc 5 functional class
LVEF 5 left ventricular ejection fraction
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At the end of the follow-up period, 96 patients (73%) had
AV disease (either pure stenosis, pure regurgitation or
both), 33 of them had AS, 90 AR. Most had mild disease
(Table 2). Twenty-seven had both AS and AR (only a single
case of mild AS with severe AR and two cases of severe AS
with mild AR). Thirty-five patients (27%) had no evidence
of AV disease (Table 2).
According to the clinical evaluation at the end of the
follow-up period, 37 patients had functional class (Fc) III
and 3 had Fc IV. Yet only two patients with severe AS and
a single patient with moderate AR had Fc III. The rest of
the patients with advanced Fc were symptomatic due to
deterioration of the mitral valve or because of diastolic
dysfunction.
Of the patients with AS at the time of mitral valve
surgery, only one progressed from mild to moderate disease
and two progressed from mild to severe AS over a mean
follow-up period of 16 6 7 years (range 2 to 33 yr, median
18).
Of those with AR, 52 with mild disease (90%) remained
stable, five (9%) progressed from mild to moderate and one
(2%) from mild to severe over a mean follow-up period of
15 6 8 years (range 1 to 33 yr, median 16).
Of the 72 patients without AV disease at the time of
mitral valve surgery, 36 acquired AV disease during the
follow-up period. Of the 26 cases of AS, 20 were mild and
6 were moderate. Of the 32 cases of AR, 31 were mild, 1
was moderate.
In only two patients (1.5%) with combined AV disease at
the time of mitral valve surgery did the AS progress
significantly (from mild to severe) after 17 and 22 years.
Later on these patients had AV replacement.
The comparison between patients who already had AV
disease at the beginning and patients who acquired AV
disease during the follow-up period is presented in a life
table (Kaplan-Meier) analysis (Fig. 1). A significant differ-
ence (p , 0.001) was found between the two groups, i.e.,
among patients with AV disease at the time of mitral valve
surgery; moderate or severe AV disease developed sooner
and in higher proportion than in patients who acquired AV
disease during the follow-up period (Fig. 1, Table 3).
After a mean of 21 years of follow-up procedures (range
15 to 33 yr), six patients of the entire cohort (5%) required
surgery for moderate to severe AV disease. Two patients
had severe AS, three had moderate AS and one had severe
AR. All were graded as NYHA functional class III–IV. In
four of them, a major consideration for surgery was also the
presence of severe prosthetic mitral valve dysfunction. These
patients had a double valve replacement.
Table 1. Demographic and Clinical Characteristics
of the Patients
Characteristics
Number
(%)
Gender
Male 44 (34)
Female 87 (66)
Age (yr) at Mitral Valve Surgery
Mean 6 SD 45 6 15
Range 12–77
Age (yr) at End of Follow-up
Mean 6 SD 61 6 13
Range 35–89
Type of Surgery
Mitral valve replacement 101
Single disk (Caster-Hall, Bjork-Shiley,
Sorin)
32
Double disk (St. Jude, Carbomedics) 20
Starr-Edwards 19
Xenograft (Hancock) 25
Unknown 5
Commissurotomy 30
Duration of Follow-up (yr)
Mean 6 SD 13 6 7
Range 1–33
Number of Patients During Follow-up
#2 years 12
#5 years 26
#10 years 61
Coronary Heart Disease* 10 (7)
Hypertension† 12 (8)
Hyperlipidemia‡ 2 (1)
*$70% obstruction of lumen ($50% in left main coronary artery); †Diastolic pressure
.90 mm Hg and systolic pressure .160 (in patients .65 yr); ‡Fasting serum
cholesterol .200 mg/dL.
Table 2. Aortic Valve Disease at the Time of Mitral Valve
Surgery and at Follow-up
Entry Follow-up
No AVD 72 35
AVD* 59 (45%) 96 (73%)
Pure AS 1 6
Mild 1 6
Pure AR 52 63
Mild 52 5
Moderate 0 4
AS/AR† 6 27
Mild 6 AS:
Mild 18
Moderate 7
Severe 2
AR:
Mild 24
Moderate 2
Severe 1
*All patients with aortic valve disease (either AS or AR). †All patients with AS and
AR (at the same time).
AR 5 aortic regurgitation; AS 5 aortic stenosis; AVD 5 aortic valve disease.
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None of the clinical factors studied (age, gender, NYHA
functional class, coronary heart disease, diabetes, hyper-
tension, hyperlipidemia and chronic renal failure) iden-
tified the patients who would eventually need AV re-
placement.
DISCUSSION
The present study is the first to show that patients with
rheumatic heart disease and mild AV disease at the time of
mitral valve surgery rarely develop hemodynamically signif-
icant AV disease and seldom require AV surgery after a long
follow-up period.
A considerable proportion of patients with valvular dis-
ease have multivalvular involvement. Follow-up studies on
patients with rheumatic heart disease have demonstrated
combined aortic and mitral valve disease in up to 99% over
a period exceeding 20 years (2–4).
The high rate of multivalvular involvement in patients
who undergo mitral valve surgery has raised the question of
the need for prophylactic AV replacement at the same time;
this decision is especially difficult when the AV disease is
moderate or less. The alternative is to carefully follow these
patients with the consideration that some may require a later
operation to replace the AV. Although this option may
potentially increase patient mortality and morbidity, it
avoids the short- and long-term risks of an unnecessary dual
valve replacement when the AV disease is stable.
To solve this controversy, the clinician must consider the
pattern of progression of AV disease which varies by its
etiology. Aortic stenosis may progress more rapidly in
patients with degenerative disease than those with rheu-
matic or congenital disease (15–17). Reports on the long-
term evolution of AS based on cardiac catheterization and
Doppler studies have demonstrated an annual increment of
0.1 to 0.14 cm2 in AV narrowing (15,18–20,21,22) and an
annual increase of 8.3 mm Hg in the peak gradient (18).
Brener et al. (18) found that disease progression was faster
in the patients who had the mildest stenosis at presentation,
progressive left ventricular hypertrophy or concomitant
mitral regurgitation that worsened over time. The progres-
sion rate may also be related to the presence of a coexisting
coronary disease or progressive leaflet calcification (23).
The linearity or nonlinearity of AS progression is multi-
factorial and may also influence the management policy.
Thoreau et al. showed a linear pattern of progression when
the AV area is large and a slower progression rate when the
severity of stenosis increased (24). Although this finding
was confirmed by others (25,26), larger studies are needed to
establish its clinical relevance.
Data on the rate of progression of chronic AR are also
limited. Recently, Padial et al. (27) studied 127 patients
with variable degrees of chronic AR. After 59 6 21 months
Figure 1. Life table (Kaplan-Meier) analysis comparing aortic valve disease progression (to moderate or severe) between patients with an
aortic valve disease at the time of mitral valve surgery and patients who acquired aortic valve disease during the follow-up period.
Table 3. Cumulative Proportion of Significant Aortic Valve
Disease-Free Patients
Years of Follow-Up Group 1 (*) Group 2 (*)
5 (yr) 0.98 6 0.01 (49) 1.0 6 0 (71)
10 (yr) 0.95 6 0.02 (34) 1.0 6 0 (57)
15 (yr) 0.83 6 0.06 (19) 1.0 6 0 (39)
20 (yr) 0.67 6 0.1 (4) 1.0 6 0 (19)
*Number of patients at risk of developing moderate or severe aortic valve disease.
Group 1: Patients with aortic valve disease at the time of mitral valve surgery. Group
2: Patients with aortic valve disease acquired during follow-up.
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of follow-up procedure, the regurgitation increased in 30%;
of these 25% had previously mild disease and 44% had
previously moderate disease. These findings show that
chronic AR is a progressive disease after several decades.
Unlike the natural history of isolated AV disease or that
associated with coronary heart disease, the natural history
and the progression pattern of AV disease in patients
undergoing mitral valve surgery are unknown. It may be that
the repair or replacement of the mitral valve may change the
flow characteristics near the AV as a result of the changes in
blood jet direction from the prosthetic valve or the forma-
tion of a subaortic obstruction by a cage and ball in the
mitral position. Thus, a different course of AV disease in the
presence of mitral valve surgery might be expected.
In the present study, we showed that AS and AR have a
slow rate of progression after mitral valve surgery, similar to
that in patients with rheumatic AV disease without mitral
valve surgery. Furthermore, AV replacement in the few
cases in which it was needed was performed at least 21 years
after the original mitral valve surgery. This exceeds the
mean interval reported in patients with asymptomatic mild
AS who underwent coronary artery bypass grafting (CABG)
and were referred later for AV replacement (23). It is
probably the different etiology of the AS (rheumatic among
most of our patients and senile in the CABG group) that is
responsible for this discrepancy.
A similar controversy exists concerning the management
of asymptomatic mild valvular disease when coronary artery
operation is indicated. Collins et al. (28) reported a 23.5%
operative mortality for reoperative AV replacement after
CABG compared with 7.6% for reoperative AV replace-
ment without CABG and 6.6% for primary AV replace-
ment with CABG. Because the risk of reoperation is high,
several investigators have advocated valve repair (if possible)
at the time of myocardial revascularization (29,30) by either
incision of the fused commissures or removal of the lumps
of calcium (usually discrete in senile disease) from the aortic
surface of the valve. This alleviates the AS and delays the
need for valve replacement without increasing the operative
risk during CABG (31).
Be that as it may, we clearly showed that, despite the
considerable number of patients with AV disease at the time
of mitral valve surgery, in only 2% of those with mild disease
was there significant progression after a mean follow-up
period of 16 years. Thus, when the severity of the AV
disease is less than moderate at the time of mitral valve
surgery, prophylactic valve replacement is probably not
justified.
Study limitations. Our study is limited by the lack of a
comparative control group of patients with mild AV disease
in whom prophylactic AV replacement or repair was per-
formed at the time of mitral valve surgery and a similar
group in whom AV replacement was performed selectively
after the follow-up period.
Because the follow-up period took time, the changes in
echocardiographic methods and improvement in equipment
must be considered. Nevertheless, we believe that our
finding was not severely biased because the echocardio-
graphic findings were supported by the clinical follow-up
findings.
Conclusions. Patients without AV disease or with mild
AV disease at the time of mitral valve surgery rarely develop
hemodynamically significant AV disease over a long
follow-up period.
The minor progression in the AV disease over a long
period of time and the increased perioperative and long-
term mortality and morbidity of a dual valve replacement do
not justify the performance of prophylactic AV replacement.
This is true for both AS and AR. Because all of the patients
in our study had rheumatic disease, this statement should be
generalized only to this subgroup of cardiac patients. Our
study does not provide an answer concerning patients with
moderate AV disease at the time of mitral valve surgery.
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